You are here:
CHAPEL HILL BISPHENOL A EXPERT PANEL CONSENSUS STATEMENT:INTEGRATION OF MECHANISMS, EFFECTS IN ANIMALS AND POTENTIAL TO IMPACT HUMAN HEALTH AT CURRENT LEVELS OF EXPOSURE
Citation:
VOM SAAL, F. S., B. T. AKINGBEMI, S. M. BELCHER, L. S. BIRNBAUM, D. A. CRAIN, M. ERIKSEN, L. J. GUILLETTE JR., R. HAUSER, J. J. HEINDEL, H. SHUK-MEI, T. IGUCHI, S. JOBLING, J. KANNO, R. A. KERI, K. E. KNUDSEN, G. A. LEBLANC, M. MARCUS, J. MCLACHLAN, J. P. MYERS, A. NADAL, R. R. NEWBOLD, N. OLEA, G. S. PRINS, C. A. RICHTER, B. S. RUBIN, C. SONNENSCHEIN, A. M. SOTO, C. E. TALSNESS, J. G. VANDENBERGH, L. N. VANDENBERG, D. R. WALSER-KUNTZ, C. S. WATSON, W. V. WELSHONS, Y. WETHERILL, AND R. T. ZOELLER. CHAPEL HILL BISPHENOL A EXPERT PANEL CONSENSUS STATEMENT:INTEGRATION OF MECHANISMS, EFFECTS IN ANIMALS AND POTENTIAL TO IMPACT HUMAN HEALTH AT CURRENT LEVELS OF EXPOSURE. REPRODUCTIVE TOXICOLOGY. Elsevier Science Ltd, New York, NY, 24(2):131-138, (2007).
Impact/Purpose:
to report on panel findings on bisphenol A
Description:
This document is a summary statement of the outcome from the meeting: “Bisphenol A: An Examination of the Relevance of Ecological, In vitro and Laboratory Animal Studies for Assessing Risks to Human Health” sponsored by the NIEHS and NIDCR, NIH/DHHS on the estrogenic environmental chemical bisphenol A (BPA, 2, 2-bis (4-hydroxyphenyl) propane; CAS# 80-05-7). The meeting was held in Chapel Hill, NC, November 28-30, 2006 due to concerns about the potential for a relationship between BPA and negative trends in human health that have occurred in recent decades. Examples include increases in abnormal penile/urethra development in males, early sexual maturation in females, an increase in neurobehavioral problems such as attention deficit hyperactivity disorder (ADHD) and autism, an increase in childhood and adult obesity and type 2 diabetes, a regional decrease in sperm count, and an increase in hormonally mediated cancers, such as prostate and breast cancers. Concern has been elevated by published studies reporting a relationship between treatment with “low doses” of BPA and many of theses negative health outcomes in experimental studies in laboratory animals as well as in vitro studies identifying plausible molecular mechanisms that could mediate such effects. Importantly, much evidence suggests that these adverse effects are occurring in animals within the range of exposure to BPA of the typical human living in a developed country, where virtually everyone is exposed to measurable blood, tissue and urine levels of BPA that exceed the levels produced by doses used in the “low dose” animal experiments.